Industry ranking
| Reporting Period | Filing Date | Average Time to Pay (days) | Paid within 30 days | Paid 31-60 days | Paid after 60 days | Not Paid within Terms |
|---|---|---|---|---|---|---|
| 01 Jan 2024 - 30 Jun 2024 | 31 Jul 2024 | 49 | 23% | 56% | 21% | 6% |
| 01 Jul 2023 - 31 Dec 2023 | 31 Jan 2024 | 27 | 70% | 22% | 8% | 15% |
| 01 Jan 2023 - 30 Jun 2023 | 20 Jul 2023 | 29 | 70% | 22% | 8% | 1% |
| 01 Jul 2022 - 31 Dec 2022 | 27 Jan 2023 | 43 | 45% | 35% | 20% | 51% |
| 01 Jan 2022 - 30 Jun 2022 | 22 Jul 2022 | 33 | 58% | 33% | 8% | 34% |
| 01 Jul 2021 - 31 Dec 2021 | 30 Jan 2022 | 33 | 52% | 38% | 10% | 53% |
| 01 Jan 2021 - 30 Jun 2021 | 30 Jul 2021 | 37 | 30% | 61% | 9% | 71% |
| 01 Jul 2020 - 31 Dec 2020 | 29 Jan 2021 | 35 | 38% | 56% | 6% | 67% |
| 01 Jan 2020 - 30 Jun 2020 | 30 Jul 2020 | 31 | 35% | 59% | 6% | 66% |
| 01 Jul 2019 - 31 Dec 2019 | 28 Jan 2020 | 25 | 78% | 22% | 1% | 17% |
| 01 Jan 2019 - 30 Jun 2019 | 29 Jul 2019 | 30 | 71% | 24% | 6% | 26% |
| 01 Jul 2018 - 31 Dec 2018 | 29 Jan 2019 | 29 | 68% | 26% | 6% | 29% |
| 01 Jan 2018 - 30 Jun 2018 | 30 Jul 2018 | 30 | 64% | 30% | 6% | 36% |
This information is as reported by the business, and responses are in their own words.
Standard payment terms
The default position is 90 days, however there may be changes to this default position on a case-by-case basis pending agreement with suppliers. On a case-by-case basis, payment terms to suppliers may be immediate payment or payment on terms within 7, 14, 30 or 60 days.
Were there any changes to the standard payment terms in the reporting period?
No information available
Any other information about payment terms
No additional information
Maximum contractual payment period agreed
90
If a supplier has a query or dispute relating to a payment they believe is owed to them by Napp Pharmaceuticals Limited (NPL), the supplier is to please email the below details, to napp.apqueries@mundipharma.com a. Full supplier name, address; b. The name of your NPL point of contact; c. Invoice number for the payment you are querying; d. Full details of your complaint; e. Upon receipt of all of the above details, NPL commits to acknowledge receipt of the supplier email within five working days, and may request further information to be able to respond in full. NPL will investigate the supplier query using the details provided and speak with relevant members of NPL’s business, including members of NPL’s legal department if necessary, and respond in full within 14 days of the date of NPL’s acknowledgement to the supplier.
Has this business signed up to a code of conduct or standards on payment practices?
For example, signatories to The Prompt Payment Code must commit to paying 95% of their invoices within 60 days.
❌
Does this business offer e-invoicing in relation to qualifying contracts?
This is where suppliers can electronically submit and track invoices. It's not just allowing suppliers to email them an invoice.
❌
Does this business offer supply chain finance?
This is where a supplier who has submitted an invoice can be paid by a third-party finance provider earlier than the agreed payment date. The business would then pay the finance provider the invoiced sum.
❌
Under its payment practices and policies, can this business deduct sums from payments under qualifying contracts as a charge for remaining on a supplier list?
❌
During the reporting period, did the business deduct sums from payments as a charge for remaining on a supplier list?
No information available
Napp Pharmaceuticals Limited, registered in Cambridge, brings medicines to the NHS in the UK. It is a member of the Mundipharma network of independent associated companies and has supplied innovative medicines to UK health professionals and patients since the 1920s. Its work includes developing and providing pharmaceutical products, including opioid analgesics for pain management, alongside branded generic medicines under its QDEM range. The company states it works closely with NHS bodies, business partners and patients, emphasising ethical marketing, transparency over payments and sponsorships, and responsible use of opioid medicines. Companies House records its nature of business as wholesale of pharmaceutical goods.
Generated from the company's website and Companies House records. Sources: napp.co.uk · napp.co.uk